Skip to main content
Thorax logoLink to Thorax
. 1984 Jun;39(6):432–435. doi: 10.1136/thx.39.6.432

Direct labelling of ipratropium bromide aerosol and its deposition pattern in normal subjects and patients with chronic bronchitis.

S G Spiro, C A Singh, S E Tolfree, M R Partridge, M D Short
PMCID: PMC459825  PMID: 6235619

Abstract

A technique for the direct labelling of ipratropium bromide with bromine-77, with reconstitution of the drug in a metered dose inhaler so as to be identical to the commercial product, was used to study drug deposition patterns in seven normal subjects and seven patients with chronic bronchitis (mean FEV1 32% (SD 12.2%) predicted normal). The gamma camera image of the thorax was divided into a middle zone--the mediastinal zone--and the lung itself into a central zone comprising its medial third and a peripheal zone, the lateral two thirds. Measurements after 10 inhalations of labelled ipratropium bromide showed similar results for the two groups of subjects. The total lung dose inhaled was 11.2% of 203 micrograms and 11.7% of 186 micrograms in the normal subjects and the patients respectively. In contrast to the deposition patterns seen in aerosol studies using steady state inhalation methods, there was no difference in deposition pattern--that is, the distribution between the central and the peripheral lung zones--between the normal subjects and the patients with airways obstruction.

Full text

PDF
432

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Davies D. S. Pharmacokinetics of inhaled substances. Postgrad Med J. 1975;51(7 Suppl):69–75. [PubMed] [Google Scholar]
  2. Dolovich M. B., Sanchis J., Rossman C., Newhouse M. T. Aerosol penetrance: a sensitive index of peripheral airways obstruction. J Appl Physiol. 1976 Mar;40(3):468–471. doi: 10.1152/jappl.1976.40.3.468. [DOI] [PubMed] [Google Scholar]
  3. Goldberg I. S., Lourenço R. V. Deposition of aerosols in pulmonary disease. Arch Intern Med. 1973 Jan;131(1):88–91. [PubMed] [Google Scholar]
  4. Newman S. P., Morén F., Pavia D., Little F., Clarke S. W. Deposition of pressurized suspension aerosols inhaled through extension devices. Am Rev Respir Dis. 1981 Sep;124(3):317–320. doi: 10.1164/arrd.1981.124.3.317. [DOI] [PubMed] [Google Scholar]
  5. Newman S. P., Pavia D., Clarke S. W. How should a pressurized beta-adrenergic bronchodilator be inhaled? Eur J Respir Dis. 1981 Feb;62(1):3–21. [PubMed] [Google Scholar]
  6. Newman S. P., Pavia D., Morén F., Sheahan N. F., Clarke S. W. Deposition of pressurised aerosols in the human respiratory tract. Thorax. 1981 Jan;36(1):52–55. doi: 10.1136/thx.36.1.52. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Short M. D., Singh C. A., Few J. D., Studdy P. R., Heaf P. J., Spiro S. G. The labelling and monitoring of lung deposition of an inhaled synthetic anticholinergic bronchodilating agent. Chest. 1981 Dec;80(6 Suppl):918–921. [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES